TALLAHASSEE, Fla. -- During an interview in Florida State coach Jimbo Fisher's office on National Signing Day in February, Fisher's cell phone wouldn't stop ringing. On a day when the Seminoles landed one of the nation's top classes, the persistent caller wasn't a recruit. As the phone kept ringing, Fisher excused himself and answered.
In 1996, when she was 4 years old, Catherine MacLean learned she had aplastic anemia. For seven years, she lived from hospital visit to hospital visit, one transfusion to the next. It wasn't until the summer of 2002 that her world suddenly included what was possible beyond the walls of her illness. She was 11.
I began taking an iron supplement because I thought I might have a case of running-induced anemia. It seemed to help, but now I wonder if I should continue taking the supplement or let it go. Am I getting too much iron?
A coroner's investigator dismissed online speculation that the pneumonia deaths of actress Brittany Murphy and her husband, Simon Monjack, may both have been related to viral mold inside their Los Angeles home.
Shares of Amgen and Johnson & Johnson took a hit Wednesday after a study showed their anti-anemia drugs increase the risk of blood clots and death in cancer patients. But the companies say it's old news.
Amgen, the nation's second-largest biotech, was once considered immune from the chronic problems facing old-line drugmakers. But these days Amgen has all the major symptoms of "Big Pharma disease:" regulatory run-ins, price competition from generic drugs, and a virtually empty pipeline of future medicines.
Lawmakers are pushing forward with legislation that could help create generic competition for Big Biotech, drastically lowering the costs of expensive biotech drugs and changing the landscape in the pharmaceutical industry forever.
Federal health officials have issued stern new warnings for doctors to more carefully prescribe widely used anemia drugs that can increase the risk of death and other serious problems in patients with cancer and kidney disease.
Drug sales, bolstered by Medicare coverage, are projected to keep rising for the next 10 years, and biotechs are expected to get the lion's share of that increase, while the more traditional Big Pharma companies get squeezed by generic drug makers.
Nokia's disappointing sales announcement and the resulting fallout in the tech sector makes a lot of nervous investors even jumpier. In particular, they fear that any earnings disappointments during the next few weeks may lead to sudden selloffs.